Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature

被引:9
|
作者
Li, Ye [1 ]
Lv, Xinna [1 ]
Wang, Bing [2 ]
Xu, Zexuan [1 ]
Wang, Yichuan [2 ]
Sun, Mengyan [1 ]
Hou, Dailun [1 ]
机构
[1] Capital Med Univ, Beijing Chest Hosp, Dept Radiol, Beijing, Peoples R China
[2] Beijing TB & Thorac Tumor Res Inst, Dept Radiol, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Radiomics; Magnetic Resonance Imaging; EGFR; T790M; Brain Metastases;
D O I
10.1016/j.acra.2022.12.030
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives: Timely identifying T790M mutation for non-small cell lung cancer (NSCLC) patients with brain metastases (BM) is essential to adjust targeted treatment strategies. To develop and validate radiomics models based on multisequence MRI for differenti-ating patients with T790M resistance from no T790M mutation in BM and explore the optimal sequence for prediction. Materials and Methods: This retrospective study enrolled 233 patients with proven of BM in NSCLC which included 95 with T790M and 138 without T790M from two hospitals as the training cohort and testing cohort separately. Radiomics features extracted from T2WI, T2 fluid-attenuated inversion recovery (T2-FLAIR), diffusion weighted imaging (DWI) and contrast-enhanced T1-weighted imaging (T1-CE) sequence respectively. The most predictable features were selected based on the maximal information coefficient and Boruta method. Then four radiomics models were built to characterize T790M mutation by random forest classifier. ROC curves, F1 score and DCA curves were constructed to validate the capability and verify the performance of four models.Results: The DWI model showed best performance with AUC and F1 score of 0.886 and 0.789 in the training cohort, 0.850 and 0.743 in the testing cohort. DCA curves also showed higher overall net benefit from the DWI model than from the remaining three models in the testing cohort. Other three models also had some classification power whether in the training or testing cohort, especially T2-FLAIR model.Conclusion: Multisequence MRI-based radiomics has potential to predict the emergence of EGFR T790M resistance mutations especially the radiomics signature based on DWI sequence.
引用
下载
收藏
页码:1887 / 1895
页数:9
相关论文
共 50 条
  • [41] Detection of T790M mutation in EGFR gene, an EGFR-TKI resistant mutation, in tumor samples unexposed to EGFR TKIs
    Koba, Hayato
    Kimura, Hideharu
    Nishikawa, Shingo
    Yoneda, Taro
    Sone, Takashi
    Kasahara, Kazuo
    CANCER RESEARCH, 2016, 76
  • [42] Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation
    Miyazaki, Kunihiko
    Tamura, Tomohiro
    Kaburagi, Takayuki
    Saito, Kazuhito
    Inagaki, Masaharu
    Yamashita, Takaaki
    Ichimura, Hideo
    Nawa, Takeshi
    Endo, Takeo
    Hayashihara, Kenji
    Kimura, Masaki
    Kurishima, Koichi
    Nakamura, Hiroyuki
    Furukawa, Kinya
    Kikuchi, Norihiro
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    ANTICANCER RESEARCH, 2018, 38 (09) : 5409 - 5415
  • [43] De novo EGFR T790M mutation in lung cancer patients harboring sensitive EGFR mutations
    Lee, Youngjoo
    Lee, Geon Kook
    Lee, Yeon-Su
    Zhang, Wenji
    CANCER RESEARCH, 2014, 74 (19)
  • [44] Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid
    Theoleyre, Sandrine
    Masson, Ingrid
    Herbreteau, Guillaume
    Vallee, Audrey
    Senellart, Helene
    Denis, Marc G.
    LUNG CANCER, 2017, 114 : 111 - 112
  • [45] DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation
    Guha, Minakshi
    Castellanos-Rizaldos, Elena
    Makrigiorgos, G. Mike
    PLOS ONE, 2013, 8 (06):
  • [46] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [47] Successful treatment with osimertinib for leptomeningeal carcinomatosis from NSCLC with the EGFR T790M mutation
    Yoshimura, Naruo
    Takahashi, Hidenori
    Kurosawa, Emiko
    Tanaka, Akiko
    Ebina, Masahito
    Ohrui, Takashi
    ANNALS OF ONCOLOGY, 2019, 30 : 139 - 139
  • [48] Lung Adenocarcinoma with Double Heterozygote EGFR mutation and Combined Resistance: ALK Translocation and EGFR T790M
    Denninghoff, V.
    Wainsztein, V.
    Cuello, M. T.
    Recondo, G.
    Rojas Bilbao, E.
    Avagnina, A.
    Recondo, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S179 - S179
  • [49] Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer
    Lee, Youngjoo
    Lee, Geon Kook
    Hwang, Jung-Ah
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    CLINICAL LUNG CANCER, 2015, 16 (01) : 46 - 50
  • [50] ROS1 Translocation as a Bystander Mutation in T790M EGFR Mutated NSCLC
    Stratmann, Jan
    Kriegsmann, Joerg
    Sulzbach, Bernd
    Thoeming, Bernd
    Serve, Hubert
    Sebastian, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1260 - S1260